Control of SARS-CoV-2 infection in rituximab-treated neuroimmunological patients

J Neurol. 2021 Jan;268(1):5-7. doi: 10.1007/s00415-020-10046-8. Epub 2020 Jul 11.

Marcel S Woo^#¹, David Steins^#², Vivien Häußler^{1

3}, Matin Kohsar², Friedrich Haag⁴, Birte Elias-Hamp⁵, Christoph Heesen^{1

3}, Marc Lütgehetmann^{6

7}, Julian Schulze Zur Wiesch^#^{8

9}, Manuel A Friese^#¹⁰

¹ Institute of Neuroimmunology and Multiple Sclerosis (INIMS), Center for Molecular Neurobiology Hamburg (ZMNH), University Medical Centre Hamburg-Eppendorf, Hamburg, Germany.
² Division of Infectious Diseases, I. Department of Medicine, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
³ Department of Neurology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
⁴ Department of Immunology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
⁵ Private Neurological Practice, Hamburg, Germany.
⁶ Institute of Microbiology, Virology and Hygiene, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
⁷ German Center for Infection Disease (DZIF), University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
⁸ Division of Infectious Diseases, I. Department of Medicine, University Medical Center Hamburg-Eppendorf, Hamburg, Germany. j.schulze-zur-wiesch@uke.de.
⁹ German Center for Infection Disease (DZIF), University Medical Center Hamburg-Eppendorf, Hamburg, Germany. j.schulze-zur-wiesch@uke.de.
¹⁰ Institute of Neuroimmunology and Multiple Sclerosis (INIMS), Center for Molecular Neurobiology Hamburg (ZMNH), University Medical Centre Hamburg-Eppendorf, Hamburg, Germany. manuel.friese@zmnh.uni-hamburg.de.

^# Contributed equally.

No abstract available

Publication types